Consulting Services
For Investors
- Lucid Diligence Briefs
- Venture Capital Trends
Case Studies
Insights
- Conference Previews
- Conference Social Media Reports
LucidWargames
QuickAnswers
LucidSearch
BioPharma and Tech News

Contact Us

Search

CagriSema

Obesity Weekly News

Obesity Video Recap—January 5, 2026

This Obesity video recap highlights major Phase 3 readouts, new regulatory…

Obesity Weekly News

Obesity Today—January 5, 2026

This Obesity roundup highlights major clinical milestones, regulatory filings,…

Obesity Weekly News

Obesity Video Recap—December 9, 2025

This biweekly obesity video recap covers major GLP-1 therapeutic advances,…

Obesity Weekly News

Obesity Today—December 9, 2025

This week’s obesity update spotlights key developments, regulatory milestones,…

Categories

Obesity News
Endocrinology News
Our Insights
Immunology News
Case studies
Hematology News
BioPharma and Tech News
Oncology News
BioPharma Strategy, CI and AI Guides
Lucid Diligence Brief
Conference Social Media Reports
Venture Capital Trends
AI in Healthcare and Digital Health
Conference Previews
Cell and Gene Therapy News
Rare Disease News
Neuroscience News
Women's Health News
Public Health News
Respiratory News
Cardiovascular News
Vaccine news

Recent Posts

Lucid Diligence Brief: CORXEL $287m Series D1 for oral GLP-1 development
Lucid Diligence Brief: Mendra $82 million Series A to support AI-enabled rare-disease therapeutics
Respiratory Video Recap—January 23, 2026
Vaccines Video Recap—January 23, 2026
Public Health Today—23 January, 2026

Tags

AACR 2025 ABO-503 AMWC Dubai Anavex Life Sciences Bicara Therapeutics Cigna coverage COVID-19 variants CTNNB1S37F de-identification DM1 DMD exon 51 Endeavor BioMedicines geneventiv therapeutics GHD Hemgenix Major depressive disorder Microsoft biosecurity Nabla neurological epidemiology nvidia NVIDIA Blackwell ofatumumab PANTHERx Rare PARADIGM PCV13 booster PDPL Plus Therapeutics ProFound Therapeutics QuantHealth R9 Rare endocrine disorders Relief Cardiovascular SaMD SEC filings sHLH STAR-101 strabismus Taho Pharmaceuticals Taysha Gene Therapies tocilizumab-anoh TranC Verismo Therapeutics Vertex Women’s Health Fund YAP signaling

Archives

Archives

LucidQuest Ventures

Accelerate Your Success

LATEST NEWS

Lucid Diligence Brief: CORXEL $287m Series D1 for oral GLP-1 development
Lucid Diligence Brief: Mendra $82 million Series A to support AI-enabled rare-disease therapeutics
Respiratory Video Recap—January 23, 2026
Vaccines Video Recap—January 23, 2026
Public Health Today—23 January, 2026

TAGS

AACR 2025 ABO-503 AMWC Dubai Anavex Life Sciences Bicara Therapeutics Cigna coverage COVID-19 variants CTNNB1S37F de-identification DM1 DMD exon 51 Endeavor BioMedicines geneventiv therapeutics GHD Hemgenix Major depressive disorder Microsoft biosecurity Nabla neurological epidemiology nvidia NVIDIA Blackwell ofatumumab PANTHERx Rare PARADIGM PCV13 booster PDPL Plus Therapeutics ProFound Therapeutics QuantHealth R9 Rare endocrine disorders Relief Cardiovascular SaMD SEC filings sHLH STAR-101 strabismus Taho Pharmaceuticals Taysha Gene Therapies tocilizumab-anoh TranC Verismo Therapeutics Vertex Women’s Health Fund YAP signaling

Consulting Services
For Investors
- Lucid Diligence Briefs
- Venture Capital Trends
Case Studies
Insights
- Conference Previews
- Conference Social Media Reports
LucidWargames
QuickAnswers
LucidSearch
BioPharma and Tech News

© 2026 LucidQuest Ventures. All rights reserved

We use cookies from third party services to offer you a better experience. Read about how we use cookies and how you can control them by clicking "Privacy Preferences".

Privacy Preference Center

Privacy Preferences

When you visit any website, it may store or retrieve information on your browser in the form of cookies. Since we respect your right to privacy, you can choose not to permit data collection from certain types of services. However, not allowing these services may impact your experience ans we are able to offer you.

Privacy Policy

Required

You read and agreed to our Privacy Policy

Tracking

We use third-party cookies that help us analyze and understand how you use this website. These cookies do not store any personal information.

Privacy Policy